Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

18.25 -0.43 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 377,424
Open 18.34
Bid (Size) 17.80 (10)
Ask (Size) 19.30 (4)
Prev. Close 18.68
Today's Range 17.95 - 18.73
52wk Range 7.800 - 28.09
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks that are showing activity before the opening bell on Monday.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC 
From Bicara Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+7.8%
+7.8%
1 Month
+62.2%
+62.2%
3 Month
+56.7%
+56.7%
6 Month
+50.1%
+50.1%
1 Year
-9.7%
-9.7%

More News

Read More
4 Biotech Stocks Seeing Explosive Momentum Gains
Via Benzinga
Topics ETFs Stocks
Bicara Therapeutics to Participate in Upcoming Investor Conferences
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results
Via Benzinga
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
Via Investor's Business Daily
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Discover the top movers in Friday's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Bicara Therapeutics Inc. - Common Stock publicly traded?
Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
What is the current price of Bicara Therapeutics Inc. - Common Stock?
The current price of Bicara Therapeutics Inc. - Common Stock is 18.25
When was Bicara Therapeutics Inc. - Common Stock last traded?
The last trade of Bicara Therapeutics Inc. - Common Stock was at 10/17/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.